Currently, the market penetration for drug-eluting stent (DES) devices ranges in the neighborhood of 60% (as high as 90% in China) and is growing at more than 7% per year worldwide. By comparison, the worldwide market for all coronary stents is currently growing at nearly 6% while the market for bare metal stents (BMS) is growing at 3% per year. Compounded annually from 2008 to 2017, the market for all coronary stents is growing at 5.3%, DES at 4.4%, and BMS at 1.6%.
The market for fully biodegradable, absorbable stents is not likely to emerge until 2013-2014. Because study results so far have shown the leading absorbable stents to hold great promise in effectively treating atherosclerosis, growth rates are expected to run well into the double-digits, forecast to grow at compounded annual growth rates in the neighborhood for 15%–20% for the first five years or more.
The relatively brief history of coronary artery disease treatment, even including surgical intervention via CABG, has demonstrated that it has a remarkable propensity to evolve in surprising ways. Surgical intervention, percutaneous intervention, the stent and drug-eluting stent solution to restenosis, the emergence of multiple invasive yet still surgical interventions, drug-coated angioplasty balloons, atherosclerotic plaque-reducing drugs, gene therapy, cell therapy…
The most forward-thinking competitors in the market for coronary artery disease (CAD) treatments have planned obsolescence in mind, whether they wish to or not.
The worldwide coronary stent market, and its larger CAD market, is part of Report #C245 from MedMarket Diligence.